CTLA4 and cancer: Interestingly, CTLA‐4 protein (whose increased activation in certain cancers is repressed by the ICI, ipilimumab) does in fact have decreased activity in certain autoimmune diseases, including inflammatory bowel disease, [1, 2] thus suggesting that an autoimmune‐like state could favor the immune response against cancer.